PVLA
Palvella Therapeutics, Inc. (PVLA) reported revenue of $42.81M for fiscal year 2023, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2023 | $42.81M | +65.3% |
| FY 2022 | $25.90M | -17.6% |
| FY 2021 | $31.42M | +7.1% |
| FY 2020 | $29.32M | -32.8% |
| FY 2019 | $43.65M | +60.2% |
| FY 2018 | $27.25M | +7.8% |
| FY 2017 | $25.27M | +333.5% |
| FY 2016 | $5.83M | +98.9% |
| FY 2015 |
Palvella Therapeutics, Inc. (PVLA) reported revenue of $42.81M for fiscal year 2023, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2023, Palvella Therapeutics, Inc.'s revenue grew from $12.43M to $42.81M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.93M |
| -45.4% |
| FY 2014 | $5.37M | -56.8% |
| FY 2013 | $12.43M | - |